Identification and Characterization of Tumorigenic Liver Cancer Stem/Progenitor Cells

Ma, Stephanie; Chan, Kwok–Wah; Hu, Liang; Lee, Terence; Wo, Jana Yim–Hung; Ng, Irene Oi–Lin; Zheng, Bo‐Jian; Guan, Xin Yuan

doi:10.1053/j.gastro.2007.04.025

Cited by 1,062 publications

(614 citation statements)

References 43 publications

Supporting

Mentioning

576

Contrasting

Order By: Relevance

“…The glycoprotein CD133 is the most widely used marker for isolating and characterizing cancer stem-like cells in various cancers, including brain, pancreatic, lung, liver, colon cancers, etc. [3][4][5][6][7] In colon cancers, it is reported that several hundred CD133 + colon cancer cells are capable of initiating tumors in immuno-deficient mice and can maintain their CD133 phenotype by consecutive in vivo passages, 8 together with the evidence that CD133 is expressed in stem cells susceptible to neoplastic transformation, 9 collectively supporting the hypothesis that CD133 is the marker for colon cancer stem cells. However, its role was argued because CD133 -colon cancer cells could equally or even more effectively initiate tumors in comparison with CD133 + cells.…”

Section: Introductionmentioning

confidence: 84%

Characterization of the conversion between CD133⁺and CD133^-cells in colon cancer SW620 cell line

Feng

Jiang

Chen

et al. 2012

Cancer Biology & Therapy

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 84%

Characterization of the conversion between CD133⁺and CD133^-cells in colon cancer SW620 cell line

Feng

Jiang

Chen

et al. 2012

Cancer Biology & Therapy

View full text Add to dashboard Cite

“…CD133 as a marker of cancer stem cells (CSCs) has been demonstrated in many cancers including lung cancer [9][10][11][12][13]. The CSCs theory indicated that subpopulation of tumor cells with stem or progenitor cell characteristics can initiate tumor formation and tumor recurrence and play essential roles in the metastatic spread of primary tumors and drug resistance [14,15].…”

mentioning

confidence: 99%

CD133 positive cells isolated from A549 cell line exhibited high liver metastatic potential

Zhang¹,

Yang²,

Sun³

et al. 2014

neo

View full text Add to dashboard Cite

Lung cancer remains a major cause of cancer-related lethality because of high incidence and recurrence in spite of significant advances in staging and therapy. In present study, we identified a subpopulation of cells isolated from the A549 cell line with marker CD133. In vivo results showed that A549 CD133 + cells displayed high liver metastatic potential. Severe liver cell damage with tumor cell invasion revealed by pathological examination and these changes were consistent with the results of serological tests where the plasma GPT and GOT level are significantly higher than that of the control group. Compared with A549 cells, A549 CD133 + cells expressed high levels of VEGF and exhibited high migration and invasion capability. In conclusion, we first reported that A549 CD133 + cells exhibited characteristic of high liver metastatic potential which makes it be a suitable model for further study of liver metastasis of lung adenocarcinoma and provide a potential platform for antimetastatic drug discovery or evaluation. Key words: human lung adenocarcinoma, liver metastasis, migration, invasion, CD133Lung cancer is one of the most aggressive neoplasms in the world [1]. Despite management and treatment of lung cancer has been improved these years, but the prognosis remains poor, the 5-year survival rate of non-small cell lung cancer (NSCLC) is no more than 15 % [2]. Approximately 50 % of NSCLC patients with stage I and II will die from recurrent disease despite conventional therapy, and nearly 70% of lung cancer patients will die from metastatic disease, even after surgical resection of the primary tumor, radiation therapy, and chemotherapy [3]. Thus, it is important to find novel effective therapies to inhibit lung cancer metastasis.The most common four metastatic sites of patients with solitary metastatic NSCLC were: bone, liver, kidney and spleen [3]. Nevertheless, the mechanism of which lung adenocarcinoma selectively disseminated to certain organs remains unknown. However, experimental reproducible animal models facilitate to understand the process of metastasis and can provide suitable models for basic or preclinical studies.Different kinds of cancer metastasis model have been published yet. Early in 1996, Iguchi H et al [4] have established lung cancer metastasis model with human lung squamous cell carcinoma-derived cells (HARA). In 1959, Leduc [5] was the first to describe liver metastasis in mice after injection of hepatoma carcinoma cells in the spleen. Moreover, the liver metastasis models in nude mice of colon carcinoma have been successfully established [6,7]. Early studies in immunodeficient mice illustrated that subcutaneous injection of tumor cells seldom give rise to liver metastases [8].However, no lung adenocarcinoma liver metastasis model has been published so far. CD133 as a marker of cancer stem cells (CSCs) has been demonstrated in many cancers including lung cancer [9][10][11][12][13]. The CSCs theory indicated that subpopulation of tumor cells with stem or progenitor cell characteristics c...

show abstract

“…Subsequently, numerous studies have focussed on the identification of reliable marker expression profiles for liver CSCs. The CD133 + subpopulation of various hepatocellular carcinoma cell lines displayed a more immature, proliferative phenotype with greater colony formation capacity in vitro and upon xenotransplantation a higher tumorigenic potential compared to the CD133 − cellular counterpart (26)(27)(28).…”

Section: Liver Progenitor Cells and Cancer Stem Cellsmentioning

confidence: 99%

Wnt/?-Catenin Signalling during Liver Metabolism, Chronic Liver Disease and Hepatocarcinogenesis

Shirolkar¹,

Pasic²,

Gogoi-Tiwari³

et al. 2018

jrenhep

View full text Add to dashboard Cite

Chronic liver diseases (CLDs) are increasing in prevalence and their end-stage complications, namely, cirrhosis, liver failure and hepatocellular carcinoma represent major global challenges. The most common initiators of progressive CLD are viral hepatitis and long-term alcohol abuse as well as steatosis and steatohepatitis. Irrespective of the underlying aetiology, a common feature of CLD is the formation of hepatic ductular reactions, involving the proliferation of liver progenitor cells (LPCs) and their signalling to fibrosis-driving hepatic stellate cells. The Wnt/β-catenin pathway has been found to regulate development, stemness and differentiation, and alterations in its activity have been associated with tumour development. Recent data highlight the role of Wnt/β-catenin signalling in hepatic metabolism, steatosis and cancer, and suggest targeting of this pathway as a promising molecular strategy to potentially inhibit CLD progression and hepatocarcinogenesis.

show abstract

Identification and Characterization of Tumorigenic Liver Cancer Stem/Progenitor Cells

Cited by 1,062 publications

References 43 publications

Characterization of the conversion between CD133⁺and CD133^-cells in colon cancer SW620 cell line

Characterization of the conversion between CD133⁺and CD133^-cells in colon cancer SW620 cell line

CD133 positive cells isolated from A549 cell line exhibited high liver metastatic potential

Wnt/?-Catenin Signalling during Liver Metabolism, Chronic Liver Disease and Hepatocarcinogenesis

Contact Info

Product

Resources

About

Identification and Characterization of Tumorigenic Liver Cancer Stem/Progenitor Cells

Cited by 1,062 publications

References 43 publications

Characterization of the conversion between CD133+and CD133-cells in colon cancer SW620 cell line

Characterization of the conversion between CD133+and CD133-cells in colon cancer SW620 cell line

CD133 positive cells isolated from A549 cell line exhibited high liver metastatic potential

Wnt/?-Catenin Signalling during Liver Metabolism, Chronic Liver Disease and Hepatocarcinogenesis

Contact Info

Product

Resources

About

Characterization of the conversion between CD133⁺and CD133^-cells in colon cancer SW620 cell line

Characterization of the conversion between CD133⁺and CD133^-cells in colon cancer SW620 cell line